Issue

Vol. 28 No. 8 (2016): Vol 28 Issue 8

Copyright (c) 2016 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Development and Validation of Stability Indicating Method for Darunavir with Forced Degradation Studies Using LC-ESI-MS/MS

https://doi.org/10.14233/ajchem.2016.19806
Minal Ghante
Sinhgad Technical Education Society's Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk.), Pune-411 048, India
Sanjay D. Sawant
Sinhgad Technical Education Society's Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk.), Pune-411 048, India

Corresponding Author(s) : Sanjay D. Sawant

drsdsawant69@gmail.com

Asian Journal of Chemistry, Vol. 28 No. 8 (2016): Vol 28 Issue 8

Abstract

Darunavir is a non-peptidic, second generation protease inhibitor used to treat HIV infection. Stability testing is main component in the pharmaceutical development program for a new drug as well as new formulation. Herewith forced degradation studies were carried out in accordance with the ICH guideline Q1A (R2). Darunavir was found to degrade in basic and oxidative stress conditions. Resolution of the drug and degradation products was achieved on a Hi-Q Sil C-18 column (4.6 × 250 mm, 5 μm) utilizing acetonitrile, water (90:10 % v/v) of pH 5 at a flow rate of 1 mL/min and at the detection wavelength 266 nm.

Keywords

Oxidative degradation Darunavir Stability indicating method LC-ESI MS/MS
Ghante, M., & Sawant, S. D. (2016). Development and Validation of Stability Indicating Method for Darunavir with Forced Degradation Studies Using LC-ESI-MS/MS. Asian Journal of Chemistry, 28(8), 1729–1733. https://doi.org/10.14233/ajchem.2016.19806
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. International Conference on Harmonization (ICH), Q1A (R2): Stability testing of New Drug Substances and Products, IFPMA, Geneva (2003).
  2. World Health Organization (WHO), Draft stability Testing of Active Pharmaceutical Ingredients and Pharmaceutical Products, Geneva (2007).
  3. Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products, EMEA, London (2002).
  4. Therapeutic Products Directorate (TPD), Guidance for Industry Stability Testing of Existing Drug Substances and Products, Health Canada, Ottawa, Canada (2003).
  5. M. Bakshi and S. Singh, J. Pharm. Biomed. Anal., 28, 1011 (2002); doi:10.1016/S0731-7085(02)00047-X.
  6. Y. Wu, Biomed. Chromatogr., 14, 384 (2000); doi:10.1002/1099-0801(200010)14:6<384::AID-BMC30>3.0.CO;2-D.
  7. G.R. Babu, A.L. Rao and J.V. Rao, Int. J. Res. Pharmacy Chem., 3, 438 (2013).
  8. B.N. Patel, B.N. Suhagia and C.N. Patel, Int. J. Pharmacy Pharm. Sci., 4, 270 (2012).
  9. R.B. Ganduri, R.A. Lanka, S. Pamidi, J.R. Peddareddigari and J.V.L.N.S. Rao, Asian J. Pharm. Res., 1, 10 (2011).
  10. M.B. Mane, P.J. Gaikawad, A.V. Patil and A.S. Mogale, Int. J. Pharm. Sci. Rev. Res., 4, 20 (2013).
  11. L. Satyanarayana, S.V. Naidu, M.N. Rao, A. Kumar and K. Suresh, Asian J. Res. Pharm. Sci., 1, 74 (2011).
  12. S.K. Mastanamma, V.S. Sirisha, G. Alekhya, K. Haritha and V.A. Babu, Int. Res. J. Pharm., 4, 13 (2014); doi:10.7897/2230-8407.050103.
  13. B.V. Reddy, G. Jyothi, B.S. Reddy, N.V. Raman, K.S. Reddy and C. Rambabu, J. Chromatogr. Sci., 51, 471 (2013); doi:10.1093/chromsci/bms165.
  14. A.C. Kogawa, J.N. Mendonca, N.P. Lopes and H.R.N. Salgado, Anal. Methods, 6, 3689 (2014); doi:10.1039/C4AY00248B.
  15. S. Singh and M. Bakshi, Pharma Technology on-line, 4, 1 (2000).
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 0